Diets · Metabolic & Cardiometabolic
magnitude of LDL reduction correlates with cardiovascular disease
In plain terms: Does lowering LDL more cut heart-attack risk more?
Leans support Diets 🔬 Includes disconfirming
Part of: 💊 statins
RefutedContestedStrong support
consensus score 0.45
Yes, per unit of LDL lowered — per-mmol meta-analyses and Mendelian randomization show the relationship is causal. But at the whole-trial level the size of a statin's LDL-lowering is a weak predictor of that trial's benefit (R-squared near zero), so this is a surrogacy gap, not proof LDL is harmless.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
9 support 2 contradict 0 tested null 3 mixed · 14 sources, 8 independent groups
What the evidence shows
Per unit of LDL lowered, cardiovascular benefit scales: the CTT per-mmol analyses and Mendelian randomization support a dose-response that is causal. But at the whole-trial level the MAGNITUDE of a statin's LDL lowering is a weak predictor of that trial's benefit (Byrne 2022; Liaigre 2025, R^2~0) - a surrogacy gap across heterogeneous trials, which Norwitz uses to attack LDL.
The evidence (18)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, Wilcox I, Keech A, Rodgers A, Lal S 2020 · Lancet Diabetes Endocrinol | meta-analysis | supports | high | 327,037 participants: consistent ~21% RR reduction per mmol/L LDL-C lowering across baseline LDL-C and risk strata. |
| Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, Packard CJ, Laufs U, Brook RD, Oliver-Williams C, Butterworth AS, Danesh J, Smith GD, Catapano AL, Sabatine MS 2017 · JAMA | observational | mixed | high | CETP/HMGCR variant study: CV benefit tracks LDL-lowering but is attenuated when LDL is lowered discordantly with ApoB. |
| Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS 2016 · JAMA | meta-analysis | supports | high | 49 trials/312,175: across statin AND non-statin LDL-lowering, RR per 1 mmol/L LDL reduction ~0.77, consistent — trial-level dose-response for benefit. |
| Hao Q, Aertgeerts B, Guyatt G, Bekkering GE, Vandvik PO, Khan SU, Rodondi N, Jackson R, Reny JL, Al Ansary L, Van Driel M, Assendelft WJJ, Agoritsas T, Spencer F, Siemieniuk RAC, Lytvyn L, Heen AF, Zhao Q, Riaz IB, Ramaekers D, Okwen PM, Zhu Y, Dawson A, Ovidiu MC, Vanbrabant W, Li S, Delvaux N 2022 · BMJ | meta-analysis | supports | high | Clinical practice guideline, not the analysis: its evidence is 'A linked systematic review and network meta-analysis (14 trials including 83 660 participants)' published separately. Abstract stratifies benefit by baseline cardiovascular risk, not by magnitude of LDL reduction; the old extract's 'proportional to additional LDL-C reduction' is not in the abstract. Review — zero weight. |
| Li X, Celotto S, Pizzol D, Gasevic D, Ji MM, Barnini T, Solmi M, Stubbs B, Smith L, López Sánchez GF, Pesolillo G, Yu Z, Tzoulaki I, Theodoratou E, Ioannidis JPA, Veronese N, Demurtas J 2021 · Eur J Clin Invest | meta-analysis | mixed | high | Off-scope: umbrella review of metformin only ('we identified 427 different meta-analyses' of metformin use); no data on LDL-reduction magnitude or statin benefit. Old extract ('anchors that magnitude-benefit links are often overstated') was an analogy, not a finding. |
| Byrne P, Demasi M, Jones M, Smith SM, O'Brien KK, DuBroff R 2022 · JAMA Intern Med | meta-analysis | contradicts | moderate | Byrne2022: weak LDL-MI corr, R2=0 for mortality/stroke; benefit not strongly LDL-mediated at trial level |
| Preiss D, Tobert JA, Hovingh GK, Reith C 2020 · JACC | meta-analysis | supports | high | Self-described review (JACC Focus Seminar): 'This review describes key stages in the evolution of LDL cholesterol-lowering treatment.' Restates CTT: 'statins lower the relative risk of major atherosclerotic events by about 22% per 38.7 mg/dl (1 mmol/l) reduction in LDL cholesterol'. No pooling of its own. Review — zero weight; CTT carries the vote. |
| Burger, Dorresteijn, Koudstaal, Holtrop, Kastelein, Jukema, Ridker, Mosterd, Visseren 2024 · Atherosclerosis | meta-analysis | supports | high | The paper's stated analysis is 'random-effects meta-regression analyses for the association between follow-up duration, age, and the HR for major vascular events per 1 mmol/L LDL-C reduction' — magnitude of LDL-C reduction is the denominator of the effect measure, not a tested predictor of effect size, so no surrogacy R^2 is produced. The prior extract also mis-stated the result: the effect did not grow over treatment time — 'Follow-up duration was not associated with a change in the HR for major vascular events (HR for change per year 0.994; 95 % CI 0.970-1.020; p = 0.66)', with the IPD sub-analysis agreeing (0.983; 0.943-1.025; p = 0.42). Headline number retained for context: 'The HR for major vascular events per 1 mmol/L LDL-C reduction was 0.78 (95 % confidence interval [CI] 0.75-0.81).' |
| Khan I, Peterson ED, Cannon CP, Sedita LE, Edelberg JM, Ray KK 2020 · J Am Heart Assoc | meta-analysis | supports | moderate | A time-dependent treatment-benefit model derived from 22 RCTs (statins and non-statins) used 'magnitude of low-density lipoprotein cholesterol reduction' as a core parameter and outperformed CTT-based estimations in predicting benefit across 15 validation trials. |
| Ennezat PV, Guerbaai RA, Maréchaux S, Le Jemtel TH, François P 2023 · J Cardiovasc Pharmacol | meta-analysis | mixed | high | Systematic review/meta-analysis of 60 RCTs (323,950 participants) found that although lipid-lowering therapy reduced all-cause mortality overall (RR 0.92), 'intensive LDL-C percent lowering was not associated with further reductions in all-cause mortality' (RR 1.00) or |
| Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL 2017 · European Heart Journal | observational | supports | high | EAS consensus: genetic, epidemiologic and trial evidence show LDL causally lowers ASCVD proportional to absolute LDL exposure. |
| Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MS 2019 · Circulation | meta-analysis | mixed | high | Per-mmol/L benefit differs by lipid lowered: LDL/ApoB-lowering predicts CV benefit whereas triglyceride-lowering does so weakly. |
| Liaigre L, Guigui A, Manceau M, Cracowski JL, Khouri C, Roustit M 2025 · Eur Heart J Cardiovasc Pharmacother | meta-analysis | contradicts | moderate | Liaigre2025 umbrella 20RCTs/194k: trial-level R2 0-0.1 LDL (valid needs>=0.65); lit discrepant; individual surrogacy holds |
| Sabatine, Wiviott, Im, Murphy, Giugliano 2018 · JAMA Cardiol. 2018 Sep 1;3(9):823-828 | meta-analysis | supports | high | Per-mmol proportionality held at very low baseline LDL-C, across three concordant estimates: statin subgroup (CTTC data, 1,922 events) RR 0.78 (95% CI 0.65-0.94); 3 nonstatin add-on trials (50,627 patients, 9,570 events) RR 0.79 (0.70-0.88); combined RR 0.79 (0.71-0.87, P < .001) per 1-mmol/L LDL-C reduction. THREE CAVEATS: the previously quoted '22%' was the paper's BACKGROUND CTTC figure at a 3.4 mmol/L baseline, not its result; the claim is about STATIN benefit while most of this paper's evidence is nonstatin add-on (ezetimibe, a PCSK9 antibody, a CETP inhibitor) and the statin CI is wide, only just excluding 1; and the paper runs no trial-level regression of LDL-reduction magnitude against benefit size, so it speaks to per-mmol proportionality rather than to the trial-level surrogacy the claim's scope line names. |
| Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, Braunwald E, Giugliano RP, Sabatine MS 2020 · Lancet | meta-analysis | supports | high | Supports, with the design caveat named. 'LDL cholesterol lowering significantly reduced the risk of major vascular events (n=3519) in older patients by 26% per 1 mmol/L reduction in LDL cholesterol (RR 0·74 [95% CI 0·61-0·89]; p=0·0019), with no statistically significant difference with the risk reduction in patients younger than 75 years (0·85 [0·78-0·92]; pinteraction=0·37).' This is a per-mmol dose-response estimate, so it is on-topic — but the proportionality is the meta-analysis's normalisation assumption applied to 'aggregated study-level data', not a trial-level surrogacy regression of benefit against achieved LDL reduction, which is the specific question this claim's nuance turns on. It also shares 24 of its 29 trials with the CTT collaboration. (Abstract-grade.) |
| Baigent, Blackwell, Emberson, Holland, Reith, Bhala, Peto, Barnes, Keech, Simes, Collins 2010 · Lancet 376(9753):1670-1681 | meta-analysis | supports | high | IPD meta-analysis, 26 RCTs / 170,000, addressing the trial-level question directly: across the 21 statin-vs-control trials 'larger absolute reductions in LDL cholesterol were associated with larger proportional reductions in risk (trend p<0.0001), but no significant residual variation remained after adjustment for LDL cholesterol differences (trend p=0.4)'; same pattern across the 5 more-vs-less-intensive trials (trend p=0.0004, residual p=0.05). Per 1.0 mmol/L, 22% fewer major vascular events (95% CI 20-24), with no dependence on baseline LDL (trend p=0.2). |
| Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS, ORION Phase III investigators 2023 · Eur Heart J | RCT | supports | moderate | Pooled ORION-9/-10/-11 phase III trial analysis: inclisiran produced a 50.6% (1.37 mmol/L) LDL-C reduction and significantly reduced composite MACE (OR 0.74, 95% CI 0.58-0.94), consistent with the expected direction of the LDL-lowering-to-CV-benefit relationship, though |
| Khan SU, Khan MU, Virani SS, Khan MS, Khan MZ, Rashid M, Kalra A, Alkhouli M, Blaha MJ, Blumenthal RS, Michos ED 2022 · Eur J Prev Cardiol | meta-analysis | supports | moderate | Achieving lower (<70) vs higher LDL-C with intensive lipid therapy reduced major events, consistent with magnitude-benefit relation. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.